Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nascent Biotech Inc NBIO

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a... see more

Recent & Breaking News (OTCQB:NBIO)

Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

Accesswire May 4, 2022

Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

Accesswire April 12, 2022

The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial

Accesswire March 8, 2022

Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

Accesswire February 23, 2022

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

Accesswire January 11, 2022

Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration

Accesswire July 13, 2021

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

Accesswire June 15, 2021

Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Accesswire June 8, 2021

Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab

Accesswire May 19, 2021

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

Accesswire May 4, 2021

Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt

Accesswire April 26, 2021

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Accesswire March 31, 2021

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

Accesswire March 24, 2021

Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

Accesswire March 2, 2021

Nascent Biotech Announces Successful Pritumumab In-Vitro Trial Data in Collaborative Covid-19 Treatment Study with Syracuse University

Accesswire February 17, 2021

Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

Accesswire October 20, 2020

Nascent Biotech Announces Key Personnel Additions in Preparation for Coming Phase One Clinical Studies

Accesswire October 7, 2020

Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars

Accesswire October 1, 2020

Nascent Biotech Inc Completes $740,000 Equity Round of Funding

Accesswire August 24, 2020

Nascent Biotech Reduces Liabilities by Over 1.8 Million Dollars

Accesswire August 11, 2020